Essent Biologics launches Wharton’s jelly-derived human mesenchymal stromal cells to further cell therapy research

Essent Continues to Broaden Its Highly Characterized, Low Passage Primary Cell Catalog

Centennial, Colo. — April 7, 2022 — Essent Biologics™, a leading supplier of adult human-derived cell and scaffold materials, today announced it has launched a new line of primary cells: Wharton’s jelly-derived Mesenchymal Stromal Cells (hWJMSC), to its growing product portfolio.

Isolated from human umbilical cord tissue, Essent’s hWJMSCs originate from a single donor and are proven to differentiate in vitro toward chondrogenic, osteogenic and adipogenic lineages. In addition, these cells have a unique secretory profile with anti-inflammatory properties–making them extremely attractive for both research and therapeutics within the regenerative medicine and tissue engineering fields.

“Our strong partnership with AlloSource allows us access to donated placentas from their Placenta Donation Program, sourcing from women 30 years and younger,” said Courtney Jurbala, Vice President of Business Operations. “We collect the cells from the research-consented donated placenta, after a new life has been born and the mother goes home with her baby. The miracle of life continues to advance the field of regenerative medicine with a simple donation.”

Rigorously characterized to ISCT guidelines, Essent’s hWJMSCs are validated to guarantee at least one million cells per vial post thaw at low passage. In addition, Essent offers flash-frozen origin tissue as a companion product for each lot of cells, the Essent Origin Sample™, so that researchers always know their source.

Essent’s non-GMP hWJMSC are available immediately for purchase, with GMP available June 2022.  Click to learn more and order today.


About Essent Biologics

Essent Biologics is setting a new standard in human-derived biomaterials and comprehensive data for research. The nonprofit biotechnology company provides low-passaged primary cells, research tissue and scaffold materials to advance regenerative medicine research from benchtop to bedside. Essent Biologics supplies products in small or large volumes and serves as a manufacturing partner by creating master cell banks and an inventory of custom products within a tailored specification. In order to ensure reliable product quality, safety and efficacy, all Essent Biologics products are developed using robust design control processes and produced under current Good Manufacturing Practices (cGMP). For more information, please visit essentbiologics.org.


Essent Biologics and Amnion Foundation partner to provide germinal-origin cells to further drug discovery and regenerative medicine research

Distribution Agreement Will Allow Access to Innovative Full-Term Placenta-Derived Cells to Support Ground-Breaking Research

Centennial, Colo. — December 14, 2021 — Essent Biologics™, a leading supplier of adult human-derived cell and scaffold materials, today announced it has entered into a global distribution partnership agreement with the Amnion Foundation, a non-profit cell bank specializing in birth-tissue related cells and services.

This distribution agreement marks the first time that several unique cell types - cytotrophoblasts, Hofbauer cells, and placental stem/stromal cells - have been made commercially available worldwide for use in regenerative medicine, toxicology, and drug development. The partnership furthers the companies’ shared mission to democratize global access to non-controversial, full-term placental tissue-derived cell types.

“We have a strong relationship with Essent Biologics and are confident in our collective ability to make birth tissue-derived cells accessible to researchers worldwide,” said Sharon Presnell, Ph.D., President and Director of Research Services. “We are thrilled to work with the team at Essent to get our unique cells in the hands of leading researchers discovering and developing new in vitro models and regenerative medicine products.”

Under the terms of the agreement, Essent Biologics customers gain access to an expanded cell product portfolio which includes following Amnion Foundation products:

  • Cytotrophoblasts (CTBs) - Germinal-origin epithelial stem cells responsible for creating a barrier between the maternal blood and the developing baby. Until recently, recovering cytotrophoblasts from a full term placenta was considered a major technical hurdle: the typical methods involved the use of preterm fetal tissue. Innovation from the team at the Amnion Foundation led to robust methods for isolating and propagating these cells from full-term placentae, after healthy delivery of the baby. 
  • Placental Stem Cells (PSC’s) - The placenta contains multiple specialized cell types,  including phenotypically stable mesenchymal stem/stromal cells, that can be expanded extensively to create large banks of cells to support research, pre-clinical, and clinical programs. The PSCs, backed by over two decades of peer-reviewed scientific publications, are now available to support research in regenerative medicine.
  • Macrophages  (Hofbauer Cells) - Highly specialized tissue macrophages, called Hofbauer cells, may play a role in the vertical transmission of infectious agents, including Zika virus, from mother to child, making this cell type of particular interest in the study of infectious disease. These tissue-specific germinal origin macrophages provide greater context for experimental outcomes compared to standard monocyte-derived macrophages.  
  • Microvascular Endothelial Cells (MVECs)Human placental MVECs are isolated from the microvasculature of full-term placenta and propagated  at either standard atmospheric oxygen tension or physiologically-relevant oxygen tension. Unlike HUVECs, which come from large adult blood vessels, MVECs are germinal in origin and more biologically relevant for regenerative medicine products and in vitro barrier models. 

“This partnership furthers our combined mission to provide our community with the highest quality of cell materials for research to move the needle in expanding regenerative medicine,” said Corey Stone, President, Essent Biologics. “This agreement will provide global access to the Amnion Foundation’s germinal-origin stem cells, a natural extension and strategic partnership to develop break-through processes and create unique, specialized products and to commercialize and provide to untapped markets.”

All four cell types and associated media products are immediately available to order at essentbiologics.org/products.


About Essent Biologics

Essent Biologics is setting a new standard in human-derived biomaterials and comprehensive data for research. The nonprofit biotechnology company provides low-passaged primary cells, research tissue and scaffold materials to advance regenerative medicine research from benchtop to bedside. Essent Biologics supplies products in small or large volumes and serves as a manufacturing partner by creating master cell banks and an inventory of custom products within a tailored specification. In order to ensure reliable product quality, safety and efficacy, all Essent Biologics products are developed using robust design control processes and produced under current Good Manufacturing Practices (cGMP). For more information, please visit essentbiologics.org.

 

About Amnion Foundation

The Amnion Foundation is a registered 501(c)3 organization located in Winston-Salem, North Carolina. As an operating 501(c)3, Amnion actively processes donated birth tissues (placenta and umbilical cord) to generate viable human cells that are provided to researchers in academia, government, and pharma to support the development of in vitro models and in vivo therapies. The Foundation provides research-grade cells and related services to clients and has both GLP- and GMP-compliant capabilities. To learn more please visit www.amnionfoundation.org.  All donations to the Amnion Foundation are tax deductible and donors are provided the opportunity to direct their funds across a spectrum of internal and external projects.


Essent Biologics announces human mesenchymal stem cells for regenerative medicine, biopharmaceutical and cell therapy research

Centennial, Colo. — June 8, 2021 — Essent Biologics™, a nonprofit biotechnology company setting a new standard in human-derived biomaterials and comprehensive data for research, today announced the launch of its human mesenchymal stem cells (hMSCs) for regenerative medicine, biopharmaceutical and cell therapy research. Essent Biologics will provide highly-characterized, low-passaged hMSCs. Each vial will contain over one million cells at thaw and have a passage level of P0 or P1 to ensure potency.

The company’s hMSCs are the first commercial hMSC product that is recovered, expanded and cryopreserved without the use of antibiotics or animal products. Additionally, with each order of hMSCs, Essent Biologics can provide full donor information coupled with a source biopsy called the Essent Origin Sample™.

This is an important milestone in getting our products into the hands of brilliant researchers, said Corey Stone, Executive Director, Essent Biologics. Our stem cells are the ideal input to your experiment, whether you are developing cell-based therapies, spheroids, bioprinted constructs, microfluidic chips or complex in vitro models.

As a strategic venture from AlloSource, a nonprofit leader in providing allografts that maximize tissue donation to help surgeons heal their patients, Essent Biologics’ hMSCs are produced under current Good Manufacturing Practices (cGMP). The company builds their hMSCs to align with International Society for Cell & Gene Therapy (ISCT) guidelines to ensure identity, function and sterility.

For additional information on the company’s product pipeline, please visit essentbiologics.org/products/.


About Essent Biologics

Essent Biologics is setting a new standard in human-derived biomaterials and comprehensive data for research. The nonprofit biotechnology company provides low-passaged primary cells, research tissue and scaffold materials to advance regenerative medicine research from benchtop to bedside. Essent Biologics supplies products in small or large volumes and serves as a manufacturing partner by creating master cell banks and an inventory of custom products within a tailored specification. In order to ensure reliable product quality, safety and efficacy, all Essent Biologics products are developed using robust design control processes and produced under current Good Manufacturing Practices (cGMP). For more information, please visit essentbiologics.org.


Essent Biologics launches with a mission to provide human-derived biomaterials and 3D biology data for cell therapy and tissue engineering

Centennial, Colo. — January 26, 2021 — Essent Biologics™, a nonprofit biotechnology company emerging from two years of stealth-mode operation, today announced its launch as a new venture to meet the growing need for human-derived biomaterials and data to the regenerative medicine research community, as well as producing key inputs for further manufacturing by clinical partners.

As a new venture from AlloSource, one of the world’s leading manufacturers of fresh cartilage tissue used for joint repair and skin allografts to heal severe burns, Essent Biologics will leverage its connection to human tissue donation by providing low passaged primary cell lines, origin tissue and comprehensive donor data to advance translational research from benchtop to bedside. The company also has the capability to serve as a biomanufacturing partner, creating a large inventory of custom products.

“We are proud to set a new standard in human-derived biomaterials for research,” said Corey Stone, Executive Director, Essent Biologics. “Essent will motivate and empower the work researchers are doing by supporting the development of innovative therapies through quality biomaterials and powerful data.”

Essent Biologics will supply highly characterized human mesenchymal stem cells (MSCs) produced under current Good Manufacturing Practices (cGMP). The company has already partnered with leading academic research and biopharmaceutical companies who excitedly await Essent Biologics’ official product launch, anticipated in April. For additional information on the company’s product pipeline, please visit essentbiologics.org.

“The work Essent is doing to help accelerate research through human clinical trials is remarkable,” said Ethan Mann, CEO of Validus Cellular Therapeutics, Inc. “We are excited to partner with such an innovative company who will support research to develop new medical solutions, and we look forward to their future growth.”

According to Allied Market Research, the Cellular Therapy and Tissue Engineering industries are some of the fastest growing in the regenerative medicine sector. The Cellular Therapy market tallied a total expenditure of $7.25 billion in 2019 and is expected to hit $48.11 billion by 2027. The Tissue Engineering market tallied a total expenditure of $2.3 billion in 2019 and is expected to hit $6.8 billion by 2027. These strong growth rates are powered by an increase in clinical trials and manufacturing throughput.


About Essent Biologics

Essent Biologics is setting a new standard in human-derived biomaterials and 3D biology data for research. The nonprofit biotechnology company provides low passaged primary cells, origin tissue and scaffolds, as well as comprehensive donor and product data to advance regenerative medicine research from benchtop to bedside. Essent Biologics supplies products in small or large volumes and serves as a manufacturing partner by creating master cell banks and an inventory of custom products within a tailored specification. To ensure reliable product quality, safety and efficacy, all Essent Biologics products are developed using robust design control processes and produced under current Good Manufacturing Practices (cGMP). For more information, please visit essentbiologics.org.